News

Discontinuation was less likely in the prospective Patient Support Program (PSP) group compared with the retrospective non-PSP group.

The rheumatology month in review for June 2024 addresses the critical role of psychological, socioeconomic, and lifestyle factors in the management of rheumatic diseases, particularly rheumatoid arthritis and fibromyalgia.

The study demonstrated clinical similarity between the proposed biosimilar and the reference products.

A review of the 20 novel drugs approved by the US Food and Drug Administration during the first half of 2024, with links to coverage from MJH Life Sciences publications.

A study presented at EULAR 2024 found anxiety, depression, and sleep disorders were significantly correlated to pain intensity.

Patients with RA and obesity exhibited worse scores for subjective measures like pain and fatigue compared to those without obesity.

Administering canakinumab prophylaxis before a pegloticase infusion prevents new gout glares induced by pegloticase + methotrexate treatment.

RA was linked to an increased risk of ischemic and hemorrhagic strokes, with further analysis revealing sex-based differences in stroke outcomes in men vs women with RA.

A study presented at EULAR 2024 suggests tophaceous gout patients may benefit from a longer pegloticase treatment course alongside urate-lowering therapy.

A study presented at EULAR 2024 found patients with RA of low socioeconomic status have a high prevalence of fatigue.

Compared to patients on stable TNFi, patients tapering TNFi to withdrawal experienced significantly more flares and had lower Boolean 2.0 remission rates.

A study presented at EULAR 2024 found fibromyalgia and worse pain, symptom severity, and depression scores were linked to a risk of low medication adherence.

More than half of patients with RA or PsA without obesity exhibited steatosis despite having low disease activity, with no differences observed based on methotrexate use and dosage.

Positive personality traits and perceived disease impact may play a larger role in explaining sleep disturbances in patients with RA than disease activity, anxiety, or depression.

Patients with RA had a greater risk of delayed cervical cancer screening, and smoking was associated with a decrease in prostate cancer screening in patients with RA.

Presented at EULAR 2024, a study suggested controlling RA disease activity may be important from a psycho-social perspective.

Findings from a 2-year extension of the Plants for Joints randomized controlled trial show promise for the long-term benefits of diet, physical activity, and stress management in RA.

Phase 2 data presented at EULAR 2024 showed gout patients on febuxostat and ruzinurad were more likely to achieve the target serum uric acid level than those on febuxostat alone.

Findings underscore the impact of socioeconomic factors on disease management and therapeutic outcomes in patients with rheumatoid arthritis from different socioeconomic classes.

Among all groups, fewer men with rheumatic disease were childless compared with controls.

Findings showed the rates of TEAEs were generally similar between upadacitinib 15 mg and active comparators in RA and PsA.

CD40L blockade with dazodalibep benefited disease activity scores, including tender and swollen joints, in patients with moderate-to-severe active RA.

Treatment with romosozumab or denosumab demonstrated comparable results among patients with either primary osteoporosis or those with rheumatoid arthritis complicated with osteoporosis over a 24-month period.

A national survey provides insight into the prevalence of arthritis based on race in the US from 2011 – 2018.

Patients who achieved early remission with upadacitinib or adalimumab following an inadequate response to methotrexate had less pain/fatigue and better physical quality of life.

Patients with the highest daily step count had a 45% lower risk of RA compared with patients in the lowest quarter (< 6818 daily steps).

The incidences of adverse events were comparable between the original and current analyses of patients with moderate to severe RA treated with filgotinib.

A study presented at EULAR 2024 found tender joint count was linked to depression and illness perception but not anxiety.

Phase 2 data showed a significant reduction in RA disease activity at Week 12 with weekly abiprubart, compared with placebo.

Phase 3 data showed patients treated with SHR0302 4 mg or 8 mg had greater improvements in ACR20 response rates and other key secondary outcomes versus placebo.